PMCF | INVESTMENT BANKING
affiliate of plante moran

MEDICAL TECHNOLOGY M&A PULSE

SECOND QUARTER 2026



OUR INSIGHTS

Medical Technology M&A regained momentum in Q2 2026, with 113 announced transactions, up 36% from Q1, returning deal activity to its 2025 pace. This rebound came despite softer public-market valuations, with the median public MedTech company trading at approximately 13.2x EV/EBITDA, down from 15.6x a year ago.

Strategic buyers drove ~60% of transactions, leveraging strong balance sheets to pursue targeted growth opportunities. Financial sponsors accounted for ~40% of activity, with participation largely focused on add-on acquisitions supporting existing platform investments.

Overall, higher deal volume alongside valuations that are still resetting created a favorable environment for acquirers. Backed by a healthy pipeline of quality assets and improving financing conditions, the sector appears well-positioned to sustain momentum through the second half of the year.

IN THIS ISSUE

Medical Technology Coverage Team

BRYAN HUGHES
Managing Director
312.602.3636
bryan.hughes@pmcf.com

MATT JAMISON
Managing Director
312.602.3583
matt.jamison@pmcf.com

MIKE BROOKS
Director
312.602.3644
mike.brooks@pmcf.com

MIKE DePROSPERO
Vice President
312.602.3541
mike.deprospero@pmcf.com

ABOUT PMCF

PMCF is an investment bank focused exclusively on middle market transactions with professionals in Chicago, Detroit, Denver, and across the globe through Corporate Finance International™ affiliates. Offering a depth of advisory services, PMCF helps clients worldwide meet their sale, acquisition, financing, and strategic growth objectives. Additional information on PMCF can be found by visiting our website, pmcf.com.

Mergers & Acquisitions	Carve-outs & Divestitures	Strategic Assessments	Capital Raising

MEDICAL TECHNOLOGY INDUSTRY EXPERTISE

In the medical technology sector, it takes a highly focused approach to execute a transaction efficiently. And it requires the constant monitoring of new procedures, technology and product development, and overall market trends. At PMCF, our Medical Technology team brings this dedication and market knowledge to every transaction.

Our transaction expertise in the medical device, bio-pharmaceutical, and healthcare sectors, combined with industry relationships and a proprietary healthcare consulting service offering, afford us a unique perspective in the industry.

Medical Devices	Contract Research	Clinical Services	Therapeutics
Healthcare	Contract Manufacturing	Behavioral Health	Managed Care
Drug Delivery	Bio-Pharmaceutical	Specialty Pharmacy	Specialty Services

SELECT PMCF MEDICAL TECHNOLOGY TRANSACTIONS

SG Balda Stevanato Group
has been acquired by
SAGE PARK

NIOWAVE *Accelerating the Fight Against Cancer®*
has received a non-dilutive investment from
NOVARTIS

plas-tech engineering EXCELLENCE IN MEDICAL MANUFACTURING
has received an investment from
H&T PRESSPART
a division of
HEITKAMP & THUMANN GROUP

rāland
has been acquired by
AKKODIS
a portfolio company of
THE ADECCO GROUP

113	Announced transactions, an 8.7% increase from Q2 2025
11.8x	Median disclosed EV/EBITDA transaction multiple
13.2x	Median public index EV/EBITDA multiple
(1.7%)	Public index median three-month stock price % change

WHAT WE'RE DISCUSSING WITH CLIENTS

Trade Policy Still Shapes MedTech Deals

Tariffs remain an important consideration in MedTech M&A. With most medical devices sold in the U.S. still manufactured overseas, the sector remains exposed to Section 232 and 301 tariffs, as well as retaliatory duties from key markets such as the EU, China, and Mexico. As a result, buyers are placing greater scrutiny on supply chain and manufacturing footprints during diligence. U.S.-based manufacturers are attracting increased interest, while contract manufacturers continue to see strong M&A activity as acquirers look to reduce tariff exposure and enhance supply chain resilience.

Connected Care Continues to Attract Strategic Capital

Healthcare providers and MedTech companies continue to invest in connected devices, remote patient monitoring, and workflow-enablement platforms as care delivery shifts beyond traditional hospital settings. Strategic buyers are prioritizing assets that improve clinical decision-making, enable real-time patient data capture, and create recurring revenue opportunities through software and service-based business models. Connected care remains one of the sector's most attractive investment themes as organizations seek to improve outcomes while lowering the cost of care.

Medical Technology Sector Description: PMCF defines the Medical Technology sector as companies involved in the development of therapeutic devices, medical equipment, diagnostic tools, and consumable and disposable medical products. It also includes distribution, contract manufacturing, and services that support these products.

MedTech M&A Summary

Trends in Medical Technology M&A

- Deal volume increased to 113 transactions in Q2 2026 from 83 in Q1, a 36% sequential gain that marked the busiest quarter since the first quarter of 2025.
- Strategic acquirers remained the market's primary driver, accounting for ~60% of deal volume as buyers leveraged strong balance sheets to pursue high-quality assets.
- Financial sponsors returned in force, completing 44 transactions compared to just 11 in Q1, as private equity firms re-engaged the market largely through platform add-on acquisitions.
- Equipment's share of deal volume declined from nearly one-third of transactions in Q1 to 7% in Q2, while Services (28%) and Therapeutic Devices (19%) led activity; Contract Manufacturing, Consumables/Disposables, and Diagnostics each contributed roughly 11–12%, reflecting broad-based demand across the sector.

MEDICAL TECHNOLOGY QUARTERLY TRANSACTION VOLUME



SHARE OF MEDICAL TECHNOLOGY M&A TRANSACTION COUNT BY SECTOR



Sources: Capital IQ, PitchBook, Company Reports, PMCF

MEDICAL TECHNOLOGY M&A TRANSACTION METRICS

Period	Mean/Median	Transaction Value ($MM)	TEV/REV	TEV/EBITDA
2026 Q2	Mean	$ 1,022.76	4.2x	13.6x
2026 Q2	Median	$ 197.96	2.1x	11.8x
2025 Q2	Mean	$ 333.14	2.5x	13.1x
2025 Q2	Median	$ 93.16	1.6x	11.6x
2025	Mean	$ 577.97	3.9x	15.8x
2025	Median	$ 36.80	1.8x	12.1x
2024	Mean	$ 615.49	5.0x	17.7x
2024	Median	$ 55.30	2.2x	11.2x
2023	Mean	$ 464.93	5.6x	14.1x
2023	Median	$ 45.00	1.8x	9.6x

- Valuations strengthened in Q2 2026, with average EV/EBITDA multiples increasing to 13.6x from 13.1x year-over-year. Average disclosed transaction value similarly rose to $1.02 billion, up from $333 million, reflecting an increase in mega-deals, including nine transactions above $1 billion and two above $10 billion in enterprise value.
- Median metrics point the same way, with median EV/EBITDA increasing to 11.8x from 11.6x a year ago, still below the 12.1x FY2025 median. The gap between the ~$198 million median deal size and the ~$1.02 billion average reflects a barbell market with a few large, richly valued transactions alongside a much broader base of smaller deals.

HEADLINE M&A TRANSACTION METRICS

MERCK

and

bio-techne®

Announced (June 2026) – Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH), a manufacturer of life science reagents, instruments, and diagnostic products for the research, diagnostics, and bioprocessing markets

$11.3B	29.0x	9.4x
Enterprise Value	*EV/EBITDA*	*EV/Revenue*

AMERICAN INDUSTRIAL PARTNERS

and

AVANOS

Announced (April 2026) – American Industrial Partners entered into a definitive agreement to acquire Avanos Medical, Inc. (NYSE:AVNS), a specialty medical device maker focused on chronic care and interventional pain management

$1.27B	19.0x	1.8x
Enterprise Value	*EV/EBITDA*	*EV/Revenue*

Sources: Capital IQ, PitchBook, Company Reports, PMCF

M&A Transaction Segments

M&A Trends by Sector, Geography, and End Market

- Geographic activity skewed increasingly domestic in Q2 2026. Transactions between U.S. buyers and U.S. targets rose to 52 from 33 a year earlier, an increase of roughly 58%, overtaking deals between international parties (42), which had been the largest category a year ago.
- Cross-border activity remained subdued in both directions. International buyers acquired 8 U.S. targets while U.S. buyers completed 11 deals abroad, together accounting for only about 17% of the total deal volume.
- By end market, Drug Delivery was the most active area, with 23 transactions, roughly one-fifth of volume, followed by Surgical, Cardiovascular, and IVD. Much of the Drug Delivery total reflects contract research, manufacturing, and pharmaceutical-services deals rather than a single clinical theme, leaving Surgical and Cardiovascular as the busiest sub-sectors.
- The composition of activity shifted from a year ago. Surgical (up from 4 to 13) and IVD (up from 2 to 10) gained ground, while Furniture/Equipment fell sharply (from 13 to 3) and Hospital Care (9 to 4) and Home Health (8 to 2) cooled.

QUARTERLY TRANSACTIONS BY SECTOR



CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2023	2024	2025	'25 Q2	'26 Q2
Int'l-to-Int'l	258	262	216	52	42
U.S.-to-Int'l	65	55	36	9	8
U.S.-to-U.S.	192	194	125	33	52
Int'l-to-U.S.	54	52	52	10	11
Total	**569**	**563**	**429**	**104**	**113**

TRANSACTIONS BY END MARKET

End Market	2023	2024	2025	'25 Q2	'26 Q2
Acute Care	8	6	12	1	3
Aesthetic	9	17	9	4	2
Cardiovascular	24	41	31	11	11
Drug Delivery	44	81	62	14	23
Furniture/Equipment	47	65	48	13	3
Home Health	12	16	17	8	2
Hospital Care	33	23	23	9	4
Infection Control	16	21	16	6	-
IVD	8	8	16	2	10
Monitor	34	17	8	-	7
Neurovascular	18	12	9	1	4
Ophthalmology	19	23	18	4	3
Ortho	35	38	47	10	8
Other	95	87	42	8	8
Respiratory	13	12	13	1	6
Support	106	52	27	8	6
Surgical	48	44	31	4	13
Total	**569**	**563**	**429**	**104**	**113**

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Public Valuation Trends

- Public MedTech stocks were mixed in Q2 2026 and broadly trailed the S&P 500, which rose 14.9%. The MedTech index slipped 1.7% for the quarter, with Diversified Diagnostic (+3.5%) and Cardiovascular (+0.6%) edging higher while Orthopedics (-8.7%) and Diversified Medical Devices (-4.0%) fell.
- Public company valuations continue to ease. The median EV/EBITDA multiple fell to 13.2x in Q2 from 13.9x in Q1, and the median revenue multiple slipped to 3.1x from 3.6x, over the same period.
- Multiple compression, not earnings, drove the quarter's decline. MedTech share prices fell just 1.7% even as the median EV/EBITDA multiple declined about 5.0%, with the revenue multiple down roughly 14% and compressing faster than the earnings multiple.

SEGMENT PERFORMANCE AND VALUATION SUMMARY (1) (2) (3)

	Industry and Segment	Stock Price % Change		EV/EBITDA % Change		Current Valuation Stats			Net Debt/ TTM EBITDA
		3 Month	1 Year	3 Month	1 Year	Fwd PE	TTM PE	EV/EBITDA	
Categories	Diversified Medical Device	-4.0%	-23.6%	-10.9%	-11.1%	16.9x	34.0x	15.0x	2.1x
	Orthopedic	-8.7%	-11.8%	-15.6%	-6.2%	11.4x	25.7x	9.9x	3.7x
	Cardiovascular	0.6%	-10.3%	-8.0%	-26.7%	24.6x	39.4x	16.7x	1.5x
	Diversified Diagnostic	3.5%	12.3%	5.5%	-10.7%	19.3x	28.0x	13.2x	2.9x
Overall Median		**-1.7%**	**-11.0%**	**-9.5%**	**-10.9%**	**18.1x**	**31.0x**	**13.2x**	**2.5x**

PMCF MEDTECH INDEX PUBLIC VALUATIONS (1) (2) (4)

	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue Multiple									
Median	4.1x	4.1x	4.1x	4.1x	3.9x	3.7x	4.4x	3.6x	3.1x
Mean	5.0x	5.1x	4.9x	4.8x	4.7x	4.6x	4.8x	4.2x	3.9x
EBITDA Multiple(1)									
Median	18.0x	16.3x	17.5x	16.7x	15.6x	15.2x	15.1x	13.9x	13.2x
Mean	18.8x	21.1x	22.5x	22.0x	19.9x	18.7x	18.9x	19.1x	15.6x

Q2 2026 CHANGE IN STOCK PRICE(3)



Source: Capital IQ
Note: Prior-period data may differ from prior editions due to subsequent disclosure, restatement, or index constituent changes

(1) Multiple of EBITDA based on EBITDA inclusive of equity income from affiliates
(2) Figures based on the last trading day of the period shown
(3) Industry and segment returns are based on price-weighted performance

PMCF Medical Technology Index

Company Name	Headquarters Location	Enterprise Value[1]	Market Cap.[1]	TTM Revenue	TTM Gross Profit	EBITDA	TTM Gross Margin	TTM EBITDA Margin	Net Debt/ EBITDA	EV/ Revenue	EV/EBITDA[2] Q2 '26	EV/EBITDA[2] Q2 '25
$ in Millions [3]												
Diversified Medical Device												
Johnson & Johnson	United States	$ 644,297	$ 611,361	$ 97,929	$ 66,729	$ 34,872	68.1%	35.6%	0.8x	6.6x	18.5x	12.4x
Novartis AG	Switzerland	326,997	286,771	56,693	42,506	23,098	75.0%	40.7%	1.8x	5.8x	14.2x	11.5x
Abbott Laboratories	United States	185,533	158,052	46,585	26,482	11,681	56.8%	25.1%	2.3x	4.0x	15.9x	21.4x
Intuitive Surgical, Inc.	United States	136,449	140,843	11,034	7,358	4,181	66.7%	37.9%	NM	12.4x	32.6x	59.8x
Stryker Corporation	United States	132,966	120,697	25,837	16,946	7,376	65.6%	28.5%	1.6x	5.1x	18.0x	26.0x
Boston Scientific Corporation	United States	73,254	63,438	20,996	14,527	5,711	69.2%	27.2%	2.1x	3.5x	12.8x	35.3x
Becton, Dickinson and Company	United States	58,161	41,698	22,484	10,553	6,121	46.9%	27.2%	2.6x	2.6x	9.5x	12.2x
Baxter International Inc.	United States	18,654	11,011	11,470	3,911	1,884	34.1%	16.4%	4.0x	1.6x	9.9x	11.9x
Median							**66.1%**	**27.9%**	**2.1x**	**4.6x**	**15.0x**	**16.9x**
Orthopedic												
Zimmer Biomet Holdings, Inc.	United States	$ 23,772	$ 16,655	$ 8,509	$ 5,946	$ 2,555	69.9%	30.0%	2.8x	2.8x	9.3x	9.4x
Smith & Nephew plc	United Kingdom	14,951	12,221	6,300	4,312	1,382	68.4%	21.9%	2.2x	2.4x	10.8x	11.4x
Globus Medical, Inc.	United States	10,042	10,725	3,145	2,169	1,010	69.0%	32.1%	NM	3.2x	9.9x	10.6x
Enovis Corporation	United States	2,572	1,192	2,278	1,390	372	61.0%	16.3%	3.7x	1.1x	6.9x	9.9x
Alphatec Holdings, Inc.	United States	1,817	1,330	815	577	38	70.8%	4.7%	12.7x	2.2x	NM	NM
Orthofix Medical Inc.	United States	511	369	833	594	21	71.3%	2.5%	7.6x	0.6x	24.4x	25.7x
Median							**69.4%**	**19.1%**	**3.7x**	**2.3x**	**9.9x**	**10.6x**
Cardiovascular												
Medtronic plc	Ireland	$ 120,546	$ 100,138	$ 36,364	$ 23,749	$ 10,103	65.3%	27.8%	2.0x	3.3x	11.9x	14.5x
Edwards Lifesciences Corporation	United States	49,098	52,087	6,512	5,069	1,997	77.8%	30.7%	NM	7.5x	24.6x	24.6x
Terumo Corporation	Japan	21,176	20,273	7,282	3,876	1,881	53.2%	25.8%	0.4x	2.9x	11.3x	16.5x
Merit Medical Systems, Inc.	United States	4,470	4,136	1,579	782	339	49.5%	21.5%	1.1x	2.8x	13.2x	21.1x
LeMaitre Vascular, Inc.	United States	2,015	2,193	262	189	83	71.9%	31.6%	NM	7.7x	24.3x	28.0x
Artivion, Inc.	United States	1,293	1,091	471	304	64	64.4%	13.5%	5.2x	2.7x	20.3x	41.4x
AngioDynamics, Inc.	United States	516	542	320	175	0	54.6%	0.1%	NM	1.6x	NM	NM
Median							**64.4%**	**25.8%**	**1.5x**	**2.9x**	**16.7x**	**22.9x**
Diversified Diagnostic												
Roche Holding AG	Switzerland	$ 355,512	$ 328,545	$ 77,920	$ 57,791	$ 29,658	74.2%	38.1%	1.0x	4.6x	12.0x	9.8x
Thermo Fisher Scientific Inc.	United States	226,349	186,316	46,336	18,992	11,739	41.0%	25.3%	3.3x	4.9x	19.3x	16.8x
Danaher Corporation	United States	148,807	134,816	25,107	14,751	8,028	58.8%	32.0%	2.9x	5.9x	18.5x	20.9x
Quest Diagnostics Incorporated	United States	29,856	23,462	11,560	3,837	2,266	33.2%	19.6%	2.5x	2.6x	13.2x	12.9x
Labcorp Holdings Inc.	United States	29,290	22,960	14,348	4,144	2,320	28.9%	16.2%	2.9x	2.0x	12.6x	14.8x
Median							**41.0%**	**25.3%**	**2.9x**	**4.6x**	**13.2x**	**14.8x**
Median							**65.4%**	**26.5%**	**2.5x**	**3.1x**	**13.2x**	**15.6x**
Mean							**60.2%**	**24.2%**	**3.1x**	**3.9x**	**15.6x**	**19.9x**

Source: Capital IQ
Note: Prior-period data may differ from prior editions due to subsequent disclosure, restatement, or index constituent changes

(1) Market capitalizations and total enterprise values as of June 30, 2026; income statement and balance sheet data as of last period reported
(2) Multiple of EBITDA based on EBITDA inclusive of equity income from affiliates
(3) Currency conversions assume historical rate

YEAR OVER YEAR % CHANGE IN CPI

The year-over-year (YoY) percentage change in the Consumer Price Index (CPI) reflects the annual rate of inflation by measuring price increases for a standardized basket of goods and services purchased by urban consumers.

As of the end of Q2 2026, the YoY CPI increase was 3.46%, up from 2.68% at the end of Q2 2025, pointing to a buildup of inflationary pressures.

FEDERAL FUNDS RATE



The Federal Funds Rate is the interest rate at which depository institutions lend reserves to one another overnight. As a key benchmark for short-term interest rates, it plays a central role in monetary policy by shaping borrowing costs, consumer spending, and broader economic activity.

As of the end of Q2 2026, the Federal Funds Rate stands at 3.63%, signaling a more stable monetary environment, as easing financial conditions continue to underpin deal momentum.

CONSUMER SENTIMENT INDEX

The University of Michigan Consumer Sentiment Index gauges the confidence of consumers in the health of the economy, based on monthly surveys assessing personal finances, business conditions, and future expectations. It serves as a leading indicator of consumer behavior and overall economic outlook.

As of the end of Q2 2026, the Consumer Sentiment Index stands at 49.5, down from 60.7 at the end of Q2 2025. This decline reflects heightened household caution driven by elevated energy prices, lingering inflation concerns, and ongoing geopolitical conflict, tempering confidence despite broader improvements in macroeconomic conditions.

Sources: PMCF Research, Federal Reserve Bank of St. Louis, University of Michigan

Venture Capital Activity Overview

U.S. venture capital set records in 2026, but almost none of it reached medical technology. Roughly $143.9 billion was deployed across U.S. VC-backed companies in Q2 2026, the second-highest quarterly total in a decade behind only Q1's record, bringing H1 2026 deal value to $412.7 billion, already nearly 30% above the entire 2025 total. Medical sectors captured $24.8 billion in H1 2026 venture dollars, or 6.0% of total funding, down from 16.0% in 2025 and 24.8% in 2023. Healthcare devices and supplies alone drew $5.4 billion, 1.3% of the market. AI absorbed $355.9 billion, or 86% of every venture dollar in the period.

For the medical companies that did raise, terms were strong but selective. Life sciences companies closed $20.0 billion across 921 deals in H1, roughly flat on dollars versus 2025 but tracking about 7% lower on deal count; fewer, larger rounds. Median pre-money valuations across the market have pushed past their 2021 highs at every series, more than doubling versus 2021 at pre-seed, seed, and Series D+, with the all-sector median Series D+ pre-money valuation reaching roughly $2.0 billion. MiRus, the transcatheter aortic valve developer, was the only medical device company among the quarter's seven U.S. venture rounds at or above $1 billion, and its lead investor was a strategic, Boston Scientific, rather than a financial sponsor.

Exit value set a record, but medical technology saw almost none of it. Q2 2026 exit value reached $1.8 trillion, anchored almost entirely by SpaceX's listing, which PitchBook values at $1.7 trillion, the largest U.S. VC-backed technology IPO on record by a factor of 17x. Excluding SpaceX, the quarter produced roughly $129 billion of exit value. PitchBook describes the IPO window as cracking open, but only narrowly, and only for AI, space technology, and crypto. Healthcare devices and supplies generated $5.5 billion in exit value in H1, and healthcare services and systems generated $5.1 billion, compared with $41.3 billion for pharma and biotech. For MedTech owners, the practical read is unchanged: the realistic path to liquidity remains a sale to a strategic acquirer or a sponsor, not a public listing.

VC INVESTMENTS IN MEDICAL SECTORS



*2026 deal count annualized at the H1 2026 run-rate

MEDIAN PRE-MONEY VALUATION BY ROUND



*H1 2026 (through June 2026)

DEAL COUNT BY ROUND



Angel/Seed: The company has a concept or product under development but is likely not fully operational. Typically, in existence less than 18 months.

Early: The company has a product or service in testing or pilot production. In some cases, the product may be commercially available. May or may not be generating revenues. Typically, in business less than three years.

Later: Product or service is widely available. Company is generating ongoing revenue; potentially positive cash flow. More likely to be, but not necessarily, profitable.

*2026 deal count and value annualized at the H1 2026 run-rate

Sources: Capital IQ, PitchBook, Company Reports, PMCF

What is a Strategic Assessment and Why is it Important?

A Strategic Assessment is a comprehensive report that examines a business holistically with specific consideration given to the financial results, operations, and organizational structure. We advise our clients consider one before a planned liquidity event to ensure your company is ready for a transaction. This process includes:

- Determining your company's current value
- Identifying factors that enhance or erode value and related risk considerations
- Developing strategies to bridge gaps in value and market position

7 Reasons Why a Strategic Assessment is Essential for Maximizing Business Value In Preparation of a Liquidity Event

1. Prepares your company for the scrutiny of capital investors
2. Helps ownership and management identify the value attributes and constraints of the business
3. Provides ownership with an understanding of perceived value considerations in the eyes of investors
4. Affords your company an opportunity to address shortfalls and enhance the value in advance of a capital transaction
5. Helps align corporate strategy with organizational, tax, and wealth transfer planning
6. Helps shareholders/management understand how various business strategies can impact future value
7. Resolves potential deal obstacles to ensure a smooth diligence process and higher likelihood of deal success

As an investment in your company, PMCF will complete a complimentary Strategic Assessment.

For additional information, please visit pmcf.com

SIGNIFICANT INDUSTRY EXPERTISE AND RESOURCES

Founded in 1995, PMCF has spent 30 years successfully advising clients in the middle market. From M&A advisory or capital raising to strategic assessment and transaction planning, we execute transactions to achieve life-changing outcomes for our clients. We leverage our significant deal experience, industry relationships, and a deep understanding of sectors we serve to support our clients' organic and inorganic growth initiatives.

PMCF takes a strategic approach to transaction planning, ensuring the positioning and messaging conveys the unique differentiators of your company. Our affiliation with Plante Moran provides us access to transaction tax experts to provide insight into structure planning considerations.

- Developing strategies to effectively deploy capital and resources to maximize ROI on your high-priority growth initiatives
- Aligning your process capabilities with key macrotrends driving industry growth
- Evaluating KPI trends and results and understanding how they are used in daily management
- Reviewing the organizational chart and the internal plan for turnover and/or succession of key management team members
- Pursuing customer diversification at attractive, appropriate margins
- Understanding margin trends and concentrations of margin within product groups or customers
- Assessing your company's differentiation and position in the marketplace
- Leveraging our extensive global relationships to help penetrate new customers and/or markets

About PMCF

OUR LOCATIONS





CHICAGO
10 S. Riverside
9th Floor
Chicago, IL 60606
Phone: 312.602.3600

DETROIT
3000 Town Center
Suite 100
Southfield, MI 48075
Phone: 248.223.3300

DENVER
8181 E. Tufts Avenue
Suite 600
Denver, CO 80237
Phone: 720.370.8181

OUR FIRM

PMCF's M&A advisory and investment banking services are designed to provide company shareholders with a trusted advisor to oversee all transaction related aspects of a company sale or strategic acquisition. Our service levels, industry expertise in Medical Technology, and approach to managing transactions goes well beyond a typical investment banker.

PMCF | INVESTMENT BANKING

- Differentiated approach via senior banker leadership and direct involvement through every step of the transaction providing a consistent and highly experienced point of contact
- One of the largest, most active investment banking boutiques with a focus on specialty niche businesses
- Proven positioning and marketing processes to obtain premium valuations in company sales
- Tailored sale process provides for extensive upfront preparation, detailed company review and identification of any potential issues in advance, and buyer evaluation/diligence ensuring the right fit
- Unique sale planning approach that helps shareholders best prepare for a future sale whether it's six months or several years
- Long-term and client First approach allows PMCF to provide unbiased feedback

Two-time winner, Boutique Investment Banking Firm of the Year by M&A Advisor

Awarded, Cross Border Corporate and Strategic Acquisition of the Year by M&A Advisor

Awarded, Cross Border M&A Deal of the Year by M&A Advisor

Awarded, 2024 Dealmaker of the Year by ACG Detroit

PMCF | INVESTMENT BANKING

10 S Riverside Plaza
9th Floor
Chicago, IL 60606